Loading clinical trials...
Loading clinical trials...
A PHASE 3B, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX(Registered) IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE
Conditions
Interventions
Nimenrix
Locations
16
Finland
Tampere Vaccine Research Clinic
Tampere, Pirkanmaa, Finland
Jarvenpaa Vaccine Research Center
Jarvenpaa, Uusimaa, Finland
Espoo Vaccine Research Clinic
Espoo, Finland
FVR, Etelä-Helsingin rokotetutkimusklinikka
Helsinki, Finland
Helsinki South Vaccine Research Clinic
Helsinki, Finland
Helsinki East Vaccine Research Clinic
Helsinki, Finland
Start Date
April 9, 2021
Primary Completion Date
September 9, 2022
Completion Date
September 9, 2022
Last Updated
March 18, 2024
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions